Drugs in Development: From Pipeline to Market 2010PharmaLive Special ReportsJune 1, 2010 196 Pages - SKU: ENPP2717581 |
More Drug Discovery reports by PharmaLive Special Reports
Drugs in Development: From Pipeline to Market 2011 by PharmaLive Special Reports
In this annual compilation, PharmaLive analysts detail information about prescription medicines in clinical development as well as those approved for marketing in the United States ...
Investigational Drug Review and Outlook 2011 by PharmaLive Special Reports
More drugs are being developed for oncology indications by pharmaceutical and biotechnology companies than for any other therapeutic grouping. Of the 100 investigational drugs recognized ...
New Drug Review and Outlook 2011 by PharmaLive Special Reports
The U.S. Food and Drug Administration approved 88 new medicines in 2010, dropping slightly compared to 92 in 2009. New molecular entity (NME) approvals also ...
Personalized Medicine & Orphan Drugs Review and Outlook 2010 by PharmaLive Special Reports
See all reports like this >>The $232 billion personalized medicine market in the U.S. is projected to grow 11% annually over the next several years. Experts believe that eventually personalized ...
More United States Drug Discovery reports
US Infectious Disease Testing Market Outlook: Innovations, Trends and Opportunities for Suppliers by Venture Planning Group
This report presents a comprehensive analysis of the US infectious disease testing market, including:Major issues pertaining to the US laboratory practice, as well as key ...
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia ...
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - US Drug Forecast ...
Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 by GlobalData
See all reports like this >>PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - US Drug Forecast ...
More United States reports
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.
See all reports like this >>D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Drug Discovery Reports